RecruitingPhase 3NCT06921785

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Sponsor

AstraZeneca

Enrollment

1,220 participants

Start Date

May 6, 2025

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma

Summary

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a Phase III study testing a new combination immunotherapy — rilvegostomig plus bevacizumab, with or without tremelimumab — as a first treatment for advanced liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed. **You may be eligible if...** - You have locally advanced or metastatic liver cancer that cannot be removed by surgery - You have not yet received any systemic (whole-body) treatment for advanced liver cancer - Your cancer is classified as BCLC stage B or C, with a Child-Pugh class A liver score - You have at least one measurable tumor on imaging - Your overall health and organ function are adequate **You may NOT be eligible if...** - You have already received systemic therapy for advanced liver cancer - You are co-infected with both hepatitis B and hepatitis C - You have uncontrolled medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTremelimumab

IV therapy

DRUGRilvegostomig

IV therapy

DRUGBevacizumab

IV therapy

DRUGAtezolizumab

IV therapy

Locations(204)

Research Site

Phoenix, Arizona, United States

Research Site

Tucson, Arizona, United States

Research Site

Palo Alto, California, United States

Research Site

Santa Monica, California, United States

Research Site

New Haven, Connecticut, United States

Research Site

Newark, Delaware, United States

Research Site

Jacksonville, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Fayetteville, Georgia, United States

Research Site

Chicago, Illinois, United States

Research Site

Shreveport, Louisiana, United States

Research Site

Detroit, Michigan, United States

Research Site

Grand Rapids, Michigan, United States

Research Site

Rochester, Minnesota, United States

Research Site

New Brunswick, New Jersey, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

Cleveland, Ohio, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Pittsburgh, Pennsylvania, United States

Research Site

Austin, Texas, United States

Research Site

Dallas, Texas, United States

Research Site

El Paso, Texas, United States

Research Site

Houston, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Tyler, Texas, United States

Research Site

Blacksburg, Virginia, United States

Research Site

Fairfax, Virginia, United States

Research Site

Seattle, Washington, United States

Research Site

Milwaukee, Wisconsin, United States

Research Site

Auchenflower, Australia

Research Site

Camperdown, Australia

Research Site

Heidelberg, Australia

Research Site

Porto Alegre, Brazil

Research Site

Santa Maria, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

Vitória, Brazil

Research Site

Edmonton, Alberta, Canada

Research Site

Halifax, Nova Scotia, Canada

Research Site

Barrie, Ontario, Canada

Research Site

Brampton, Ontario, Canada

Research Site

Cambridge, Ontario, Canada

Research Site

Ottawa, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Québec, Quebec, Canada

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Changsha, China

Research Site

Chengdu, China

Research Site

Chifeng, China

Research Site

Chongqing, China

Research Site

Deyang, China

Research Site

Fuzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Guiyang, China

Research Site

Harbin, China

Research Site

Hefei, China

Research Site

Hohhot, China

Research Site

Kunming, China

Research Site

Linyi, China

Research Site

Lishui, China

Research Site

Luoyang, China

Research Site

Nanchang, China

Research Site

Nanchang, China

Research Site

Nanjing, China

Research Site

Nanning, China

Research Site

Nantong, China

Research Site

Neijiang, China

Research Site

Shandong, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Shenyang, China

Research Site

Weifang, China

Research Site

Wenzhou, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Zhengzhou, China

Research Site

Clichy, France

Research Site

Lille, France

Research Site

Lyon, France

Research Site

Nantes, France

Research Site

Nice, France

Research Site

Pessac, France

Research Site

Rennes, France

Research Site

Toulouse, France

Research Site

Aachen, Germany

Research Site

Berlin, Germany

Research Site

Bonn, Germany

Research Site

Dortmund, Germany

Research Site

Dresden, Germany

Research Site

Essen, Germany

Research Site

Frankfurt, Germany

Research Site

Frankfurt, Germany

Research Site

Göttingen, Germany

Research Site

Hamburg, Germany

Research Site

Hanover, Germany

Research Site

Leipzig, Germany

Research Site

Lübeck, Germany

Research Site

Magdeburg, Germany

Research Site

Moers, Germany

Research Site

München, Germany

Research Site

Regensburg, Germany

Research Site

Ulm, Germany

Research Site

Hong Kong, Hong Kong

Research Site

Shatin, Hong Kong

Research Site

Ahmedabad, India

Research Site

Bangalore, India

Research Site

Binnāguri, India

Research Site

Dehradun, India

Research Site

Delhi, India

Research Site

Hyderabad, India

Research Site

Mumbai, India

Research Site

Nashik, India

Research Site

Vadodara, India

Research Site

Bologna, Italy

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Palermo, Italy

Research Site

Perugia, Italy

Research Site

Pisa, Italy

Research Site

Roma, Italy

Research Site

Rozzano, Italy

Research Site

Bunkyō City, Japan

Research Site

Chiba, Japan

Research Site

Fukuoka, Japan

Research Site

Hiroshima, Japan

Research Site

Hiroshima, Japan

Research Site

Iizuka-shi, Japan

Research Site

Kashiwa, Japan

Research Site

Kita-gun, Japan

Research Site

Kobe, Japan

Research Site

Kōtoku, Japan

Research Site

Kumamoto, Japan

Research Site

Kurume-shi, Japan

Research Site

Kyoto, Japan

Research Site

Matsuyama, Japan

Research Site

Mitaka-shi, Japan

Research Site

Morioka, Japan

Research Site

Musashino-shi, Japan

Research Site

Nagoya, Japan

Research Site

Okayama, Japan

Research Site

Osaka, Japan

Research Site

Osakasayama-shi, Japan

Research Site

Saga, Japan

Research Site

Sapporo, Japan

Research Site

Sendai, Japan

Research Site

Suita-shi, Japan

Research Site

Tokyo, Japan

Research Site

Toyoake-shi, Japan

Research Site

Tsu, Japan

Research Site

Yokohama, Japan

Research Site

Yokohama, Japan

Research Site

Amsterdam, Netherlands

Research Site

Groningen, Netherlands

Research Site

Maastricht, Netherlands

Research Site

Rotterdam, Netherlands

Research Site

Utrecht, Netherlands

Research Site

Busan, South Korea

Research Site

Goyang-si, South Korea

Research Site

Gyeonggi-do, South Korea

Research Site

Seongnam-si, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

Barcelona, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Santander, Spain

Research Site

Changhua, Taiwan

Research Site

Kaohsiung City, Taiwan

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Tainan County, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan, Taiwan

Research Site

Bangkok, Thailand

Research Site

Bangkok, Thailand

Research Site

Chiang Mai, Thailand

Research Site

Dusit, Thailand

Research Site

Hat Yai, Thailand

Research Site

Muang, Thailand

Research Site

Ubonratchathani, Thailand

Research Site

Altındağ, Turkey (Türkiye)

Research Site

Ankara, Turkey (Türkiye)

Research Site

Erzurum, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Izmir, Turkey (Türkiye)

Research Site

Cambridge, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

Research Site

Manchester, United Kingdom

Research Site

Hanoi, Vietnam

Research Site

Ho Chi Minh City, Vietnam

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06921785

Related Trials

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT044727671 location

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT069022461 location

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

NCT072747741 location

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

NCT067102231 location